Results 201 to 210 of about 171,978 (359)

Recent Advances of In Situ Anticancer Nanomedicine from Enzyme‐Instructed Self‐Assembly

ChemNanoMat, EarlyView.
This review summarizes advances in enzymatic self‐assemblies for generating in situ anticancer nanomedicine over the past five years. It highlights the unique features of enzyme substrates for in situ anticancer nanomedicine by discussing the representative examples.
Linrui Zou, Meihui Yi, Bing Xu
wiley   +1 more source

Expression of FoxP3 in oral squamous cell carcinoma and its biological significance. [PDF]

Discov Oncol
Jiang L, Zhang Y, Zhu C, Song L, Ma Z, Liu H, Su Z, Xia M, Li J.   +8 more
europepmc   +1 more source

Suppression of Experimental Autoimmune Myasthenia Gravis by Granulocyte-Macrophage Colony-Stimulating Factor Is Associated with an Expansion of FoxP3+ Regulatory T Cells [PDF]

, 2006
Jian Rong Sheng, Liangcheng Li, Balaji Ganesh, Chenthamarakshan Vasu, Bellur S. Prabhakar, Matthew N. Meriggioli   +5 more
openalex   +1 more source

Spatial analysis of tumor immune microenvironment of TNBC with different neoadjuvant chemotherapy outcomes using multiplex Immunofluorescence. [PDF]

Breast Cancer Res
Park I, Shin SJ, Go H, Ko J, Bae SJ, Ahn SG, Jeong J, Kim JH, Cha YJ.   +8 more
europepmc   +1 more source

G Protein-Coupled Receptor 83 Overexpression in Naive CD4+CD25− T Cells Leads to the Induction of Foxp3+ Regulatory T Cells In Vivo [PDF]

, 2006
Wiebke Hansen, Karin Loser, Astrid M. Westendorf, Dunja Bruder, Susanne Pfoertner, Christiane Siewert, Jochen Huehn, Stefan Beissert, Jan Buer   +8 more
openalex   +1 more source

Profiling a Neo‐Antigen‐Driven Immune Response in Healthy Volunteers: A Randomized, Double‐Blind, Placebo‐Controlled Study of the KLH Challenge Model

Clinical Pharmacology &Therapeutics, EarlyView.
Novel compounds targeting the adaptive immune system are commonly initially investigated in healthy volunteers (HV). HV frequently lack constitutively expressed drug‐target engagement biomarkers, complicating the evaluation of pharmacological activity. The keyhole limpet hemocyanin (KLH) neo‐antigen challenge elicits a controlled immune response in HV ...
Micha N. Ronner, Hendrika W. Grievink, Mahdi Saghari, Michelle Osse, Thierry P.P. van den Bosch, Jeffrey Damman, Marieke L. de Kam, Jacobus Burggraaf, Naomi B. Klarenbeek, Manon A. A. Jansen, Matthijs Moerland   +10 more
wiley   +1 more source

Beyond the Classical Triad: Atypical Presentations and Regulatory T Cell Phenotyping in a Cohort of IPEX Patients. [PDF]

J Clin Immunol
Yaz I, Oskay Halacli S, Ipsir C, Ulum B, Soyak Aytekin E, Bildik HN, Ocak M, Avci H, Okur FV, Hizarcioglu Gulsen H, Demir H, Metin A, Ozon A, Kuskonmaz B, Tezcan I, Esenboga S, Cagdas D.   +16 more
europepmc   +1 more source

CD8 blockade promotes the expansion of antigen-specific CD4+ FOXP3+ regulatory T cells in vivo [PDF]

, 2006
Z. Wang, Joanna D. Davies
openalex   +1 more source

Foundational Principles for the Quantitative Translation of T‐Cell Therapeutics for Hematologic Malignancies and Immunology

Clinical Pharmacology &Therapeutics, EarlyView.
T‐cell engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells (CAR‐T cells) are among precision medicine therapies that have revolutionized the treatment of hematologic cancers. Their success in oncology has piqued interest in translating this promise into additional indications, such as autoimmune disorders.
Peter Ashcroft, Sarah McFann, Alex Ferguson, Arthur Van De Vyver, Suzanne Gaudet, Eshita Khera, Jan‐Frederik Schlender   +6 more
wiley   +1 more source

Chronic inflammation drives epididymal tertiary lymphoid structure formation and autoimmune fertility disorders in mice. [PDF]

Nat Commun
Elizagaray ML, Barrachina F, Avenatti MC, Bastepe I, Chen A, Odriozola A, Ukairo O, Da Ros VG, Ottino K, Subiran N, Battistone MA.   +10 more
europepmc   +1 more source